Interrogation of IDH1 Status in Gliomas by Fourier Transform Infrared Spectroscopy

Simple Summary Gliomas represent the vast majority of primary brain tumours and are of significant medical importance due to the poor clinical course of affected patients. The isocitrate dehydrogenase 1 (IDH1) mutation is associated with improved prognosis, compared to patients with IDH1-wildtype lesions of the same stage. In this proof-of-concept study, Fourier transform infrared spectroscopy was used to determine the IDH1 molecular status in fixed glioma sections. Classification algorithms successfully distinguished the two IDH1 classes with high accuracies (>80%). Knowledge of the IDH1 status would be beneficial, as maximum resection may be preferred in patients with IDH1-mutant gliomas, whilst a more limited resection can be best for IDH1-wildtype gliomas. Furthermore, we examined blood serum in an attempt to identify the biomolecular alterations caused by the IDH1 mutation. Non-invasive approaches that can detect the molecular status may guide some patients to an alternative treatment prior to surgery. Abstract Mutations in the isocitrate dehydrogenase 1 (IDH1) gene are found in a high proportion of diffuse gliomas. The presence of the IDH1 mutation is a valuable diagnostic, prognostic and predictive biomarker for the management of patients with glial tumours. Techniques involving vibrational spectroscopy, e.g., Fourier transform infrared (FTIR) spectroscopy, have previously demonstrated analytical capabilities for cancer detection, and have the potential to contribute to diagnostics. The implementation of FTIR microspectroscopy during surgical biopsy could present a fast, label-free method for molecular genetic classification. For example, the rapid determination of IDH1 status in a patient with a glioma diagnosis could inform intra-operative decision-making between alternative surgical strategies. In this study, we utilized synchrotron-based FTIR microanalysis to probe tissue microarray sections from 79 glioma patients, and distinguished the positive class (IDH1-mutated) from the IDH1-wildtype glioma, with a sensitivity and specificity of 82.4% and 83.4%, respectively. We also examined the ability of attenuated total reflection (ATR)-FTIR spectroscopy in detecting the biomolecular events and global epigenetic and metabolic changes associated with mutations in the IDH1 enzyme, in blood serum samples collected from an additional 72 brain tumour patients. Centrifugal filtration enhanced the diagnostic ability of the classification models, with balanced accuracies up to ~69%. Identification of the molecular status from blood serum prior to biopsy could further direct some patients to alternative treatment strategies.